LNC
28
3
SPG
45
2
ROK
46
3
DOV
48
2
O
26
16
AEE
51
3
AIZ
61
5
DG
14
6
TXN
29
4
APA
30
5
GILD
55
5
AEP
45
5
CCI
30
2
BMY
40
-5
HD
43
8
PNC
48
6
ADI
54
4
MPC
28
3
DRI
74
5
AKAM
50
2
LNC
28
3
SPG
45
2
ROK
46
3
DOV
48
2
O
26
16
AEE
51
3
AIZ
61
5
DG
14
6
TXN
29
4
APA
30
5
GILD
55
5
AEP
45
5
CCI
30
2
BMY
40
-5
HD
43
8
PNC
48
6
ADI
54
4
MPC
28
3
DRI
74
5
AKAM
50
2
Financhill
Back

Entrada Therapeutics 10K Form

Sell
37

TRDA
Entrada Therapeutics

Last Price:
$17.23
Seasonality Move:
-24.47%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TRDA News And Ratings

See the #1 stock for the next 7 days that we like better than TRDA

TRDA Financial Statistics

Sales & Book Value

Annual Sales: $129M
Cash Flow: $-24.9M
Price / Cash Flow: 0
Annual Sales: $11.30
Price / Book: 1.56

Profitability

EPS (TTM): 1.59000
Net Income (TTM): $55M
Gross Margin: --
Return on Equity: 17.06%
Return on Assets: 10.56%

Entrada Therapeutics Earnings Forecast

Key Entrada Therapeutics Financial Ratios

  • The Research & Development expenses have been 77.42% of Revenue.
  • The Net Earning history of TRDA is -5.18% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 2 years.

Entrada Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: TRDA
Website: entradatx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.59
Quick Ratio: 6.4

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

TRDA Technical Analysis vs Fundamental Analysis

Sell
37
Entrada Therapeutics (TRDA) is a Sell

Is Entrada Therapeutics a Buy or a Sell?